Andrew Ambrosy to Angiotensin-Converting Enzyme Inhibitors
This is a "connection" page, showing publications Andrew Ambrosy has written about Angiotensin-Converting Enzyme Inhibitors.
Connection Strength
1.406
-
Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists. J Am Coll Cardiol. 2020 09 01; 76(9):1034-1048.
Score: 0.702
-
Management of Renin-Angiotensin-Aldosterone System blockade in patients admitted to hospital with confirmed coronavirus disease (COVID-19) infection (The McGill RAAS-COVID- 19): A structured summary of a study protocol for a randomized controlled trial. Trials. 2021 Feb 05; 22(1):115.
Score: 0.181
-
Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med. 2019 02 07; 380(6):539-548.
Score: 0.155
-
The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol. 2014 Apr 01; 63(12):1123-1133.
Score: 0.111
-
Influence of documented history of coronary artery disease on outcomes in patients admitted for worsening heart failure with reduced ejection fraction in the EVEREST trial. Eur J Heart Fail. 2013 Jan; 15(1):61-8.
Score: 0.101
-
A randomized controlled trial of renin-angiotensin-aldosterone system inhibitor management in patients admitted in hospital with COVID-19. Am Heart J. 2022 May; 247:76-89.
Score: 0.048
-
Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial. JAMA Cardiol. 2020 02 01; 5(2):202-207.
Score: 0.042
-
Association between systolic ejection time and outcomes in heart failure by ejection fraction. Eur J Heart Fail. 2020 07; 22(7):1174-1182.
Score: 0.042
-
The impact of chronic obstructive pulmonary disease in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST Trial. J Card Fail. 2012 Jul; 18(7):515-23.
Score: 0.025